Advertisement

CNS Drugs

pp 1–6 | Cite as

Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS)

  • Amichai Perlman
  • Maor Wanounou
  • Rachel Goldstein
  • Lotan Choshen Cohen
  • Daniel E. Singer
  • Mordechai MuszkatEmail author
Short Communication
  • 87 Downloads

Abstract

Introduction

Factor Xa-inhibiting direct oral anticoagulants (FXa-DOACs) undergo hepatic metabolism via cytochrome P-450 (CYP450). Concomitant use of rifampicin, an inducer of these enzymes, with FXa-DOACs, has been shown to decrease FXa-DOAC concentrations in healthy subjects. Several common antiepileptic drugs (AEDs) are known to induce CYP450 enzymes as well. However, little is known regarding the impact of this potential interaction on treatment outcomes with FXa-DOACs.

Methods

We analyzed adverse event cases submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from January 2013 to December 2018. We compared the proportion of cases reporting thromboembolic and ischemic adverse events (TAIAEs) with the concomitant use of FXa-DOACs and enzyme-inducing AEDs to the proportion of cases with FXa-DOACs and other AEDs.

Results

During this period, 9693 adverse event cases reported concomitant use of FXa-DOACs and AEDs. Almost all reports (> 99%) involved the use of rivaroxaban or apixaban. Compared with other AEDs, enzyme-inducing AEDs were associated with an 86% increase in the odds of reporting TAIAEs [reporting odds ratio (ROR) 1.86, 95% confidence interval (CI) 1.61–2.15; p < 0.0001]. In secondary separate analyses of rivaroxaban and apixaban, enzyme-inducing AEDs were similarly associated with increased reporting of a TAIAE (ROR 1.79, 95% CI 1.50–2.12, and ROR 1.88, 95% CI 1.41–2.48, respectively).

Conclusion

Using real world data, we observed an increase in the odds of reporting anticoagulation treatment failure among patients treated with FXa-DOACs and concomitant enzyme-inducing AEDs compared to those treated with other AEDs.

Notes

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this article.

Conflict of interest

A Perlman is a doctoral student at the Hebrew University of Jerusalem and an employee at K-health Inc. The work presented in this article is not related to his work at K-health. M. Wanounou, R. Goldstein, L. Choshen Cohen, D. Singer, and M. Muszkat declare that they have no potential conflicts of interest that might be relevant to this work.

Supplementary material

40263_2019_677_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 18 kb)

References

  1. 1.
    Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016.  https://doi.org/10.1161/jaha.116.003725.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.  https://doi.org/10.1056/NEJMoa0905561.CrossRefPubMedGoogle Scholar
  3. 3.
    Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.  https://doi.org/10.1056/NEJMoa1107039.CrossRefPubMedGoogle Scholar
  4. 4.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.  https://doi.org/10.1056/NEJMoa1009638.CrossRefGoogle Scholar
  5. 5.
    Caldeira D, Barra M, Pinto FJ, Ferreira JJ, Costa J. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol. 2015;262(3):516–22.  https://doi.org/10.1007/s00415-014-7462-0.CrossRefPubMedGoogle Scholar
  6. 6.
    Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93.  https://doi.org/10.1093/eurheartj/ehy136.CrossRefPubMedGoogle Scholar
  7. 7.
    Vakkalagadda B, Frost C, Byon W, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs. 2016;16(2):119–27.  https://doi.org/10.1007/s40256-015-0157-9.CrossRefPubMedGoogle Scholar
  8. 8.
    Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013;11(1):10.  https://doi.org/10.1186/1477-9560-11-10.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mendell J, Chen S, He L, Desai M, Parasramupria DA. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig. 2015;35:447–53.  https://doi.org/10.1007/s40261-015-0298-2.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Serra W, Li Calzi M, Coruzzi P. Left atrial appendage thrombosis during therapy with rivaroxaban in elective cardioversion for permanent atrial fibrillation. Clin Pract. 2015;5(3):788.  https://doi.org/10.4081/cp.2015.788.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Stöllberger C, Finsterer J. Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy. Neurol Neurochir Pol. 2017;51(2):194–6.  https://doi.org/10.1016/j.pjnns.2017.01.010.CrossRefPubMedGoogle Scholar
  12. 12.
    Risselada AJ, Visser MJ, van Roon EN. Pulmonary embolism due to interaction between rivaroxaban and carbamazepine. Ned Tijdschr Geneeskd. 2013;157(52):A6568.PubMedGoogle Scholar
  13. 13.
    Burden T, Thompson C, Bonanos E, Medford AR. Lesson of the month 2: pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine. Clin Med. 2018;18(1):103–5.  https://doi.org/10.7861/clinmedicine.18-1-103.CrossRefGoogle Scholar
  14. 14.
    King PK, Stump TA, Walkama AM, Ash BM, Bowling SM. Management of phenobarbital and apixaban interaction in recurrent cardioembolic stroke. Ann Pharmacother. 2018;52(6):605–6.  https://doi.org/10.1177/1060028018759938.CrossRefPubMedGoogle Scholar
  15. 15.
    Di Gennaro L, Lancellotti S, De Cristofaro R, De Candia E. Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant Therapy. J Thromb Thrombolysis. 2019;48:528.  https://doi.org/10.1007/s11239-019-01866-1.CrossRefPubMedGoogle Scholar
  16. 16.
    Perlman A, Hochberg-Klein S, Cohen LC, et al. Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. J Thromb Thrombolysis. 2019;47(4):590–5.  https://doi.org/10.1007/s11239-018-01804-7.CrossRefPubMedGoogle Scholar
  17. 17.
    Calizo RC, Bhattacharya S, Hasselt JGCV, Wei C, Wong JS, Wiener RJ, et al. Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity. Nat Commun. 2019.  https://doi.org/10.1038/s41467-019-09936-x.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012.  https://doi.org/10.1126/scitranslmed.3003377.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483–6.  https://doi.org/10.1002/pds.677.CrossRefPubMedGoogle Scholar
  20. 20.
    Center for Drug Evaluation and Research. National Drug Code Directory. U.S. Food and Drug Administration. 2019. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory. Accessed 13 June 2019.
  21. 21.
    Cytochrome P-450 CYP3A4 inducers. DrugBank. 2019. https://www.drugbank.ca/categories/DBCAT003896. Accessed 13 June 2019.
  22. 22.
    Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants. Ann Pharmacother. 2013;47(11):1478–87.  https://doi.org/10.1177/1060028013504741.CrossRefPubMedGoogle Scholar
  23. 23.
    Washam JB, Hohnloser SH, Lopes RD, et al. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. J Thromb Thrombolysis. 2019;47(3):345–52.  https://doi.org/10.1007/s11239-019-01823-y.CrossRefPubMedGoogle Scholar
  24. 24.
    Medication Guides. accessdata.fda.gov. 2019. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page. Accessed 13 June 2019.
  25. 25.
    Medicines. European Medicines Agency. 2019. https://www.ema.europa.eu/en/medicines. Accessed 13 June 2019.
  26. 26.
    Macha K, Marsch A, Siedler G, Breuer L, Strasser EF, Engelhorn T, Schwab S, Kallmünzer B. Cerebral ischemia in patients on direct oral anticoagulants. Stroke. 2019;50(4):873–9.  https://doi.org/10.1161/STROKEAHA.118.023877.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Amichai Perlman
    • 1
    • 2
  • Maor Wanounou
    • 3
  • Rachel Goldstein
    • 1
    • 3
  • Lotan Choshen Cohen
    • 3
  • Daniel E. Singer
    • 4
  • Mordechai Muszkat
    • 3
    Email author
  1. 1.Division of Clinical Pharmacy, School of Pharmacy, Faculty of MedicineThe Hebrew University of JerusalemJerusalemIsrael
  2. 2.K-Health IncTel AvivIsrael
  3. 3.Department of MedicineHadassah Hebrew University HospitalJerusalemIsrael
  4. 4.Division of General Internal MedicineMassachusetts General Hospital, and Harvard Medical SchoolBostonUSA

Personalised recommendations